title: Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use Disorder.
abstract: As is the case with other drugs of abuse, a proportion of ecstasy users develop symptoms consistent with a substance use disorder (SUD). In this paper, we propose that the pharmacology of MDMA, the primary psychoactive component of ecstasy tablets, changes markedly with repeated exposure and that neuroadaptations in dopamine and serotonin brain systems underlie the shift from MDMA use to MDMA misuse in susceptible subjects. Data from both the human and laboratory animal literature are synthesized to support the idea that (1) MDMA becomes a less efficacious serotonin releaser and a more efficacious dopamine releaser with the development of behaviour consistent with an SUD and (2) that upregulated serotonin receptor mechanisms contribute to the development of the MDMA SUD via dysregulated inhibitory control associated with the trait of impulsivity.
authors.affiliation: School of Psychology, Victoria University of Wellington, Wellington, New Zealand. Susan.Schenk@vuw.ac.nz.
authors.forename: Susan
authors.initials: S
authors.lastname: Schenk
authors.affiliation: School of Psychology, Victoria University of Wellington, Wellington, New Zealand.
authors.forename: Dane
authors.initials: D
authors.lastname: Aronsen
mesh_terms: D000222:Adaptation, Physiological; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007175:Impulsive Behavior; D007266:Inhibition, Psychological; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*; D019966:Substance-Related Disorders / Q000209:etiology / Q000378:metabolism*
chemical_list: D011985:Receptors, Serotonin; D012701:Serotonin; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004298:Dopamine
keywords: Dopamine; Ecstasy; Impulsivity; Inhibitory control; MDMA; Serotonin; Substance use disorder